Cancer and multiple sclerosis patients insured by Medicare are among those awaiting lower drug prices from the new Inflation Reduction Act.
Jackie Trapp has incurable blood cancer and takes a chemotherapy drug that cost more than $240,000 last year.
Even with a Medicare drug plan, the Muskego, Wisconsin, woman said she was charged $21,740 in out-of-pocket costs last year for Revlimid. The nest egg she and her husband built has dwindled and now the couple “lives on the edge.”
Read More: Inflation Reduction Act targets Medicare drug prices, consumer costs